BioNTech (BNTX)
(Delayed Data from NSDQ)
$107.34 USD
-0.16 (-0.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $107.40 +0.06 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BNTX 107.34 -0.16(-0.15%)
Will BNTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNTX
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know
Other News for BNTX
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
BioNTech Q2 2025 Earnings Preview
Experts helping vaccine advisors are reportedly ousted at CDC
A Look Ahead: BioNTech's Earnings Forecast
Pfizer/BioNTech lose appeal to reverse Moderna’s COVID vaccine patent win in U.K.